Nature Medicine 13, 1264 (2007)
doi:10.1038/nm1007-1264
Corrigenda: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
Sandeep T Patil,
Lu Zhang,
Ferenc Martenyi,
Stephen L Lowe,
Kimberley A Jackson,
Boris V Andreev,
Alla S Avedisova,
Leonid M Bardenstein,
Issak Y Gurovich,
Margarita A Morozova,
Sergey N Mosolov,
Nikolai G Neznanov,
Alexander M Reznik,
Anatoly B Smulevich,
Vladimir A Tochilov,
Bryan G Johnson,
James A Monn
&
Darryle D Schoepp
Introduction
Nat. Med. 13, 1102–1107 (2007); published online 2 September 2007; corrected after print 17 September 2007
In the version of this article initially published, the name of one person acknowledged was misspelled, and reference 4 should have been:
Moghaddam, B. & Adams, B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281, 1349–1352 (1998).
These errors have been corrected in the HTML and PDF versions of the article.
